Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase
AUTOR(ES)
Marsden, C. D.
RESUMO
Thirty patients with Parkinson's disease were treated for four weeks with levodopa combined with an inhibitor of extracerebral dopa decarboxylase, L-alpha-methyldopahydrazine (MK 486). The therapeutic results were compared with the effects of treatment of a group of 40 patients with levodopa alone. Patients treated with the combined therapy improved more rapidly, had less nausea and vomiting, and required a much smaller dose of levodopa than patients treated with levodopa by itself.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=494269Documentos Relacionados
- Effects of levodopa alone and in combination with dopa-decarboxylase inhibitors on plasma renin activity in patients with Parkinson's disease.
- Brocresine in Parkinson's disease: Action of a peripheral and central decarboxylase inhibitor in potentiating levodopa
- An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy
- Altered thalamic response to levodopa in Parkinson’s patients with dopa-induced dyskinesias
- Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
